Antibe Therapeutics Inc.
Antibe Therapeutics Inc. (ATBPF) Revenue
Annual & quarterly revenue history · segment & region breakdown
ATBPF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAntibe Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-03-31 | $0.00B | +$0.00B | — |
| 2022-03-31 | $0.00B | -$0.01B | -100.00% |
| 2021-03-31 | $0.01B | +$0.00B | +0.49% |
| 2020-03-31 | $0.01B | +$0.00B | +1.33% |
| 2019-03-31 | $0.01B | +$0.00B | +12.09% |
| 2018-03-31 | $0.01B | -$0.00B | -6.01% |
| 2017-03-31 | $0.01B | +$0.00B | +104.06% |
| 2016-03-31 | $0.00B | +$0.00B | +22132.80% |
| 2015-03-31 | $0.00B | +$0.00B | — |
| 2014-03-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Antibe Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Antibe Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Antibe Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ATBPF revenue · 4 questionsATBPF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Antibe Therapeutics Inc. SEC filings · GAAP · Antibe Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026